Medincell SA (MEDCL.PA) stock: key figures, P/E, revenue and dividend

Health Care · France · ISIN FR0004065605

Price
26.26 EUR
Market cap
942.84 m EUR
P/E (2026)
–
P/S (2026)
49.62
Dividend yield
0.00 %
Net margin
-163.16 %
Return on equity (ROE)
-1,011.75 %
Return on assets (ROA)
-28.69 %

Medincell SA financials

Fiscal year20252026
Revenue25.00 m EUR19.00 m EUR
Gross profit25.00 m EUR19.00 m EUR
Operating income-10.76 m EUR–
EBIT-13.00 m EUR-25.00 m EUR
Net income-18.00 m EUR-31.00 m EUR
Diluted EPS – continuing operations-0.56 EUR-0.87 EUR

Full history since 2016, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About Medincell SA

MedinCell S.A. engages in the research and development of biodegradable polymer-based processes for the controlled and prolonged delivery of active pharmaceutical ingredients into the human body and animals in France. The company offers UZEDY, a subcutaneous risperidone for the treatment of schizophrenia. It also develops mdc-TJK, a subcutaneous injection, which is in NDA stage for the treatment of schizophrenia; and mdc-CWM, a sustained-release formulation of celecoxib, which is in Phase III clinical trial for the treatment and reduction of post-operative pain and inflammation. In addition, the company engages in the development of products in preclinical stage, including mdc-WWM for contraception; mdc-STM for the treatment of malaria; and mdc-AbbVie-1. It has strategic collaborations with TEVA, AIC, ABBVIE, Unitaid, and Gates Foundation. The company was incorporated in 2003 and is headquartered in Jacou, France.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.